XML 32 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Condensed Statements of Comprehensive Income (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Income Statement [Abstract]        
Net sales $ 174,961 $ 179,255 $ 545,052 $ 559,262
Cost of sales 78,547 83,831 245,028 258,240
Gross profit 96,414 95,424 300,024 301,022
Selling and administrative expense 71,237 73,476 219,081 228,375
Research and development expense 6,910 7,108 20,674 19,393
Medical device excise tax 1,334 1,427 4,052 4,413
Other expense 14,484 4,608 20,520 8,514
Total operating expenses 93,965 86,619 264,327 260,695
Income from operations 2,449 8,805 35,697 40,327
Loss on early extinguishment of debt 0 0 0 263
Interest expense 1,540 1,382 4,572 4,131
Income before income taxes 909 7,423 31,125 35,933
Provision (benefit) for income taxes (1,063) 1,736 10,272 10,221
Net income 1,972 5,687 20,853 25,712
Comprehensive income $ (4,173) $ 7,583 $ 17,001 $ 26,337
Per share data:        
Basic (per share) $ 0.07 $ 0.21 $ 0.76 $ 0.93
Diluted (per share) $ 0.07 $ 0.20 $ 0.75 $ 0.91
Dividends per share of common stock (per share) $ 0.20 $ 0.15 $ 0.60 $ 0.45
Weighted average common shares:        
Basic (shares) 27,454 27,518 27,354 27,744
Diluted (shares) 27,688 27,834 27,777 28,111